11.11.2009 • News

Arch Chemicals Q2 Profit Slips

Arch Chemicals said that second-quarter profit fell as lower volumes and unfavourable foreign exchange rates offset higher pricing and the favorable impact of the Advantis acquisition. Net earnings declined to $30.9 million, or $1.23 per share, from $33.2 million, or $1.33 per share, a year earlier, the Norwalk, Connecticut-based company said. Revenue fell to $414.2 million from $469.6 million.

Interview

Navigating Uncertainty and Driving Innovation
Meeting Pharma’s Demand for Speed, Reliability, and Flexibility

Navigating Uncertainty and Driving Innovation

Axplora CCO Arul Ramadurai discusses navigating industry uncertainty, building strategic partnerships, and advancing flexible pharmaceutical manufacturing

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read